Form 4: Akebia Therapeutics SVP Sells Shares to Cover Tax Obligations
SEC Form 4
Nicole R. Hadas, SVP and Chief Legal Officer of Akebia Therapeutics, sold 12,016 shares of common stock on May 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On May 13, 2024, Nicole R. Hadas, the SVP and Chief Legal Officer of Akebia Therapeutics, Inc., sold 12,016 shares of the company's common stock.
- The shares were sold at a price of $1.26 per share.
- The sale was executed automatically by the issuer to cover tax withholding obligations associated with the vesting and settlement of restricted stock units granted on May 12, 2023.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted by Hadas on November 14, 2023.
- Following the transaction, Hadas directly owns 651,243 shares of Akebia Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction to cover tax obligations. It doesn't convey strong positive or negative sentiment.
Industry Context
Sales to cover tax obligations are a routine part of equity compensation and are not necessarily indicative of the officer's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| May 12, 2023 | Date of grant of restricted stock units that triggered the tax withholding obligation. |
| November 14, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| May 13, 2024 | Date of the stock sale transaction. |
| May 14, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.